Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

146 7 Immunosuppresive Factors in Cancer
action to macrophage-mediated suppression.
Oncol. Res. 6: 219.
166 Hihara, J.,Y. Yamaguchi, K. Minami,
K. Noma and T. Toge. 1999. Down-regulation
of IL-10 enhances the efficacy of
locoregional immunotherapy using
OK-432 against malignant effusion. Anticancer
Res. 19: 1077.
167 Kim, B. G., H. G. Joo, I. S. Chung,
H. Y. Chung, H. J. Woo and Y. S. Yun.
2000. Inhibition of interleukin-10 (IL-
10) production from MOPC 315 tumor
cells by IL-10 antisense oligodeoxynucleotides
enhances cell-mediated immune
responses. Cancer Immunol. Immunother.
49: 433.
168 Matar, P.,V. R. Rozados, A. D. Gonzalez,
D. G. Dlugovitzky, R. D. Bonfil
and O. G. Scharovsky. 2000. Mechanism
of antimetastatic immunopotentiation
by low-dose cyclophosphamide.
Eur. J. Cancer 36: 1060.
169 Seo, N.,Y. Tokura, M. Takigawa and
K. Egawa. 1999. Depletion of IL-10±
and TGF-b-producing regulatory gd T
cells by administering a daunomycinconjugated
specific monoclonal antibody
in early tumor lesions augments
the activity of CTLs and NK cells.
J. Immunol. 163: 242.
170 Di Carlo, E., A. Coletti, A. Modesti,
M. Giovarelli, G. Forni and P. Musiani.
1998. Local release of interleukin-10
by transfected mouse adenocarcinoma
cells exhibits pro- and anti-inflammatory
activity and results in a delayed
tumor rejection. Eur. Cytokine
Netw. 9: 61.
171 Sun, H., P. Gutierrez, M. J. Jackson,
N. Kundu and A. M. Fulton. 2000. Essential
role of nitric oxide and interferon-g
for tumor immunotherapy with
interleukin-10. J. Immunother. 23: 208.
172 Bass, K. K. and M. J. Mastrangelo.
1998. Immunopotentiation with lowdose
cyclophosphamide in the active
specific immunotherapy of cancer. Cancer
Immunol. Immunother. 47:1.
173 Dray, S. and M. B. Mokyr. 1989. Cyclophosphamide
and melphalan as immunopotentiating
agents in cancer therapy.
Med. Oncol. Tumor Pharmacother. 6:
77.
174 Matar, P.,V. R. Rozados, S. I. Gervasoni
and O. G. Scharovsky. 2001.
Down regulation of T-cell-derived IL-10
production by low-dose cyclophosphamide
treatment in tumor-bearing rats
restores in vitro normal lymphoproliferative
response. Int. Immunopharmacol.
1: 307.
175 Bloom, B. R. and B. Bennett. 1966.
Mechanism of a reaction in vitro associated
with delayed-type hypersensitivity.
Science 153: 80.
176 David, J. R. 1966. Delayed hypersensitivity
in vitro: its mediation by cell-free
substances formed by lymphoid cellantigen
interaction. Proc. Natl Acad. Sci.
USA 56: 72.
177 Bernhagen, J., T. Calandra,
R. A. Mitchell, S. B. Martin, K. J. Tracey,W.
Voelter, K. R. Manogue,
A. Cerami and R. Bucala. 1993. MIF is
a pituitary-derived cytokine that potentiates
lethal endotoxaemia. Nature 365:
756.
178 Calandra, T., L. A. Spiegel, C. N. Metz
and R. Bucala. 1998. Macrophage migration
inhibitory factor is a critical
mediator of the activation of immune
cells by exotoxins of Gram-positive bacteria.
Proc. Natl Acad. Sci. USA 95:
11383.
179 Metz, C. N. and R. Bucala. 1997. Role
of macrophage migration inhibitory
factor in the regulation of the immune
response. Adv. Immunol. 66: 197.
180 Metz, C. N. and R. Bucala. 2000. MIF.
In: Feldmann, M., Durum, S., Nicola,
N.,Vilchek, J. and Hirano, T. (eds), Cytokine
Reference. Academic Press, New
York.
181 Leech, M., C. Metz, L. Santos,T. Peng,
S. R. Holdsworth, R. Bucala and
E. F. Morand. 1998. Involvement of
macrophage migration inhibitory factor
in the evolution of rat adjuvant arthritis.
Arthritis Rheum. 41: 910.
182 Mikulowska, A., C. N. Metz, R. Bucala
and R. Holmdahl. 1997. Macrophage
migration inhibitory factor is involved
in the pathogenesis of collagen
type II-induced arthritis in mice. J. Immunol.
158: 5514.
183 Leech, M., C. Metz, L. Santos,T. Peng,
S. R. Holdsworth, R. Bucala and